Steven King Net Worth

The estimated Net Worth of Steven R. King is at least $631 Thousand dollars as of 17 May 2024. Steven King owns over 612 units of Jaguar Health Inc stock worth over $1,984 and over the last 8 years he sold JAGX stock worth over $0. In addition, he makes $628,677 as Executive Vice President - Sustainable Supply and Ethnobotanical Research and Intellectual Property and Secretary at Jaguar Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Steven King JAGX stock SEC Form 4 insiders trading

Steven has made over 5 trades of the Jaguar Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 612 units of JAGX stock worth $692 on 17 May 2024.

The largest trade he's ever made was exercising 13,333 units of Jaguar Health Inc stock on 5 April 2022 worth over $15,066. On average, Steven trades about 746 units every 39 days since 2016. As of 17 May 2024 he still owns at least 1,756 units of Jaguar Health Inc stock.

You can see the complete history of Steven King stock trades at the bottom of the page.

Steven King biography

Dr. Steven R. King Ph.D. serves as Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary of the Company. He was promoted to Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property in March 2020. From 2002 to 2014, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at our wholly-owned subsidiary, Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a Ph.D. in Biology from the Institute of Economic Botany of the New York Botanical Garden and an M.S. in Biology from the City University of New York.

What is the salary of Steven King?

As the Executive Vice President - Sustainable Supply and Ethnobotanical Research and Intellectual Property and Secretary of Jaguar Health Inc, the total compensation of Steven King at Jaguar Health Inc is $628,677. There are 1 executives at Jaguar Health Inc getting paid more, with Lisa Conte having the highest compensation of $1,433,160.

How old is Steven King?

Steven King is 62, he's been the Executive Vice President - Sustainable Supply and Ethnobotanical Research and Intellectual Property and Secretary of Jaguar Health Inc since 2014. There are 4 older and 9 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.

What's Steven King's mailing address?

Steven's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.

Insiders trading at Jaguar Health Inc

Over the last 9 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski, and Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.

What does Jaguar Health Inc do?

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/

Complete history of Steven King stock trades at Jaguar Health Inc

Jaguar Health Inc executives and stock owners

Jaguar Health Inc executives and other stock owners filed with the SEC include:

• Lisa Conte,
  President, Chief Executive Officer, Director
• Steven King,
  Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
• Lisa A. Conte,
  Founder, CEO, Pres & Director
• Jonathan Wolin,
  Chief of Staff, General Counsel and Chief Compliance Officer
• Jonathan S. Wolin CPA, J.D., M.B.A.,
  Chief of Staff, Chief Compliance Officer & Gen. Counsel
• Dr. Steven R. King,
  Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
• James Bochnowski,
  Independent Chairman of the Board
• Jonathan Siegel,
  Independent Director
• Jiahao Qiu,
  Independent Director
• John Micek,
  Independent Director
• Gregory Divis,
  Independent Director
• Melissa Yeager,
  Senior Vice President - Regulatory Affairs & Quality Assurance
• Carol Lizak,
  Senior Vice President - Finance, Chief Accounting Officer
• Melissa A. Yeager J.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Ian H. Wendt M.B.A.,
  Chief Commercial Officer
• David Sesin,
  Chief Manufacturing Officer
• Dr. Karen Brunke Ph.D.,
  Exec. VP of Corp. & Bus. Devel.
• Peter Hodge,
  Sr. Director of Investor Relations, Bus. Devel. & Special Events
• Dr. Pravin R. Chaturvedi Ph.D.,
  Chair of Scientific Advisory Board & Acting Chief Scientific Officer
• Carol R. Lizak,
  Chief Financial Officer
• Roger J. Waltzman,
  Chief Scientific Officer
• Folkert W. Kamphuis,
  Director
• Philippe Brianceau,
  Chief Veterinary Officer
• Murray David Mac Naughtan,
  
• Zhi Yang,
  Director
• Ari Azhir,
  Director
• Karen Steil Wright,
  CFO and Treasurer
• Jeffery C. Johnson,
  
• Jonathan M Glaser,
  
• Bryan Bryan Ezralow 1994 Tr...,
  
• Investments Ltd Burford Cap...,
  
• Capital Partners, L.P.Sagar...,
  
• John A Kallassy,
  CFO, COO, Treasurer
• Management, Ltd.Kunlun Phar...,
  
• Michael Hauser,
  Chf Veterinarian, Clinical Ops
• Anula Jayasuriya,
  Director
• Pravin R Chaturvedi,
  Chief Scientific Officer